MX2019006098A - Ensayo de anticuerpos. - Google Patents

Ensayo de anticuerpos.

Info

Publication number
MX2019006098A
MX2019006098A MX2019006098A MX2019006098A MX2019006098A MX 2019006098 A MX2019006098 A MX 2019006098A MX 2019006098 A MX2019006098 A MX 2019006098A MX 2019006098 A MX2019006098 A MX 2019006098A MX 2019006098 A MX2019006098 A MX 2019006098A
Authority
MX
Mexico
Prior art keywords
test sample
liver cancer
mammalian subject
antibody
detecting
Prior art date
Application number
MX2019006098A
Other languages
English (en)
Spanish (es)
Inventor
Allen Jared
MacDonald Isabel
Murray Andrea
Welberry Christopher
Original Assignee
Oncimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncimmune Ltd filed Critical Oncimmune Ltd
Publication of MX2019006098A publication Critical patent/MX2019006098A/es

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2019006098A 2016-11-25 2017-11-24 Ensayo de anticuerpos. MX2019006098A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1619954.9A GB201619954D0 (en) 2016-11-25 2016-11-25 Antibody assay
PCT/GB2017/053541 WO2018096351A1 (en) 2016-11-25 2017-11-24 Antibody assay

Publications (1)

Publication Number Publication Date
MX2019006098A true MX2019006098A (es) 2019-12-02

Family

ID=58073509

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019006098A MX2019006098A (es) 2016-11-25 2017-11-24 Ensayo de anticuerpos.

Country Status (12)

Country Link
US (1) US20190376975A1 (cg-RX-API-DMAC7.html)
EP (1) EP3545309B1 (cg-RX-API-DMAC7.html)
JP (1) JP7249284B2 (cg-RX-API-DMAC7.html)
KR (1) KR20190088510A (cg-RX-API-DMAC7.html)
CN (2) CN108107218B (cg-RX-API-DMAC7.html)
AU (1) AU2017365931A1 (cg-RX-API-DMAC7.html)
CA (1) CA3044492A1 (cg-RX-API-DMAC7.html)
GB (1) GB201619954D0 (cg-RX-API-DMAC7.html)
IL (1) IL266857A (cg-RX-API-DMAC7.html)
MX (1) MX2019006098A (cg-RX-API-DMAC7.html)
RU (1) RU2769987C2 (cg-RX-API-DMAC7.html)
WO (1) WO2018096351A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109116023B (zh) * 2018-06-14 2021-06-04 郑州大学第一附属医院 一种肺癌标志物抗-mmp12自身抗体及其应用
CN109633165B (zh) * 2018-12-18 2021-03-09 中国医学科学院基础医学研究所 抗hspa4自身抗体作为乳腺癌诊断或预后评估标志物的应用
CN109709335B (zh) * 2018-12-18 2020-10-27 中国医学科学院基础医学研究所 热休克蛋白hspa4在肿瘤转移预测、预后评估和治疗中的应用
US20220314021A1 (en) * 2019-02-19 2022-10-06 Otsuka Electronics Co., Ltd. Method for determining condition parameters for photodynamic therapy and photodynamic therapy apparatus
CN110579611B (zh) * 2019-09-18 2023-01-31 郑州大学 一种用于肺癌早期筛查和诊断的联合检测血清标志物、试剂盒及检测方法
WO2022118947A1 (ja) * 2020-12-04 2022-06-09 富士フイルム和光純薬株式会社 抗体を測定する方法およびキット
CN114994318A (zh) * 2022-06-16 2022-09-02 深圳上泰生物工程有限公司 一种用于检测akr1b10的试剂盒及其制备方法
CN116444680B (zh) * 2022-12-28 2024-05-03 杭州凯保罗生物科技有限公司 一种ralgds-krt8-aif1融合肿瘤抗原蛋白的制备方法及其应用
CN119639903B (zh) * 2025-01-17 2025-11-25 中山大学肿瘤防治中心(中山大学附属肿瘤医院、中山大学肿瘤研究所) 用于肝内胆管癌的生物标记物、药物及其应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7387881B2 (en) * 2001-09-19 2008-06-17 The Regents Of The University Of Michigan Detection and treatment of cancers of the liver
ITPD20030264A1 (it) * 2003-10-30 2005-04-30 Xeptagen Spa Metodo di diagnosi altamente specifico per neoplasie
TWI281473B (en) * 2003-12-19 2007-05-21 Ind Tech Res Inst Biomarkers for liver diseases and method for using same
CN1632589A (zh) * 2003-12-24 2005-06-29 财团法人工业技术研究院 肝脏疾病的生物标记分子及其检测方法
JP2010509598A (ja) * 2006-11-13 2010-03-25 ライフ テクノロジーズ コーポレーション 前立腺癌バイオマーカーを検出するための方法およびキット
TWI530686B (zh) * 2008-12-02 2016-04-21 財團法人工業技術研究院 用於肝纖維化診斷之生物標記
EP2405269B8 (en) * 2009-03-05 2016-10-12 National Institute of Advanced Industrial Science And Technology Method for detecting and distinguishing intrahepatic cholangiocarcinoma
US20120309034A1 (en) * 2010-02-12 2012-12-06 Nitto Boseki Co., Ltd. METHOD FOR MEASURING IMMUNITY OF COMPLEX OF Ku86 AND AUTOANTIBODY THEREOF, KIT USED THEREFOR, AND METHOD FOR DETERMINING CANCER USING SAME
CN102175864A (zh) * 2011-01-19 2011-09-07 江苏永鼎股份有限公司 一组早期肝癌分子标志物及其应用
CN102507938B (zh) * 2011-10-08 2014-12-24 复旦大学附属中山医院 一种肝癌转移预测定量抗体芯片及试剂盒
EP2875356A1 (en) * 2012-07-23 2015-05-27 INSERM - Institut National de la Santé et de la Recherche Médicale Method for diagnosing scleroderma
JP2014240771A (ja) * 2013-06-11 2014-12-25 日東紡績株式会社 Ku70/Ku86ヘテロダイマーに対する自己抗体の免疫測定方法、それに用いるキットおよびそれを用いた癌判定方法
GB201320061D0 (en) * 2013-11-13 2013-12-25 Electrophoretics Ltd Materials nad methods for diagnosis and prognosis of liver cancer
GB201411060D0 (en) * 2014-06-20 2014-08-06 Oncimmune Ltd Improved immunoassay method
MY195045A (en) * 2014-07-02 2023-01-04 Dragon Victory Dev Ltd Specific Biomarker Set For Non-Invasive Diagnosis of Liver Cancer
CN104990905B (zh) * 2015-06-30 2017-12-29 曲凯 一种基于固相酶联免疫荧光斑点的肝癌转移诊断试剂盒

Also Published As

Publication number Publication date
IL266857A (en) 2019-07-31
EP3545309A1 (en) 2019-10-02
KR20190088510A (ko) 2019-07-26
RU2769987C2 (ru) 2022-04-12
JP7249284B2 (ja) 2023-03-30
CN108107218A (zh) 2018-06-01
JP2020515826A (ja) 2020-05-28
CA3044492A1 (en) 2018-05-31
AU2017365931A1 (en) 2019-06-06
GB201619954D0 (en) 2017-01-11
BR112019010636A2 (pt) 2019-10-01
US20190376975A1 (en) 2019-12-12
WO2018096351A1 (en) 2018-05-31
RU2019118625A3 (cg-RX-API-DMAC7.html) 2021-03-31
RU2019118625A (ru) 2020-12-25
CN108107218B (zh) 2021-10-08
CN113655224A (zh) 2021-11-16
EP3545309B1 (en) 2021-03-31

Similar Documents

Publication Publication Date Title
MX374652B (es) Ensayos para detectar la presencia o la cantidad de un anticuerpo antifármaco.
MX390772B (es) Métodos para tratar cáncer y el uso de biomarcadores como predictor de sensibilidad clínica a terapias.
MX377315B (es) Predicción in vitro de semivida in vivo de anticuerpos.
JOP20200216A1 (ar) تجارب للكشف عن التنكس العصبي
EA202090290A1 (ru) ПРИМЕНЕНИЕ БЕЛКА Cas, СПОСОБ ДЛЯ ОБНАРУЖЕНИЯ ЦЕЛЕВОЙ МОЛЕКУЛЫ НУКЛЕИНОВОЙ КИСЛОТЫ И НАБОР
EA201492105A1 (ru) Иммунотерапия злокачественных опухолей путем нарушения передачи сигналов pd-1/pd-l1
EA201992748A1 (ru) Диагностические анализы для обнаружения, количественного определения и/или отслеживания микроорганизмов и других аналитов
EA201370063A1 (ru) Фосфолипидом рака
MX368099B (es) Biomarcadores para predecir y evaluar el grado de respuesta de sujetos con cancer de endometrio a compuestos de tipo lenvatinib.
EA202091810A1 (ru) Антитела к b7-h4 и способы их применения
BR112016019836A2 (pt) método para analisar uma amostra de um sujeito, dispositivo de diagnóstico para utilização no diagnóstico da endometriose, kit, uso de um biomarcador, e, método para aumentar uma resposta de anticorpos em um sujeito
EP3907509A3 (en) Diagnosis of early stage pancreatic cancer
MX392040B (es) Estandares de antigeno prostatico y sus usos.
MX358772B (es) Metodo para detectar cancer.
EA201792289A1 (ru) Способы обнаружения агглютинации и композиции для их осуществления
WO2018064013A8 (en) METHODS FOR TREATING CANCER WITH BAVITUXIMAB BASED ON LEVELS OF β2-GLYCOPROTEIN 1, AND ASSAYS THEREFOR
BR112014031958A2 (pt) bag3 como marcador de tecido e soro bioquímico
MX2022013738A (es) Ensayo de anticuerpos neutralizantes para proteinas terapeuticas.
MX377026B (es) Biomarcadores para la progresión de enfermedades en melanoma.
MX2020009363A (es) Un método para detectar magea4.
MX384485B (es) Deteccion temprana de preeclampsia.
MX2019000591A (es) Tira mejorada de ensayo de analisis de orina de bajo volumen de muestra, kits analiticos y metodos de uso relacionados con la misma.
HK1254818A1 (zh) 抗原肽及其用於诊断和治疗自闭症的用途
MX374731B (es) Método para la detección de un anticuerpo igm específico para un flavivirus en una muestra.
EA201400571A1 (ru) Специфичные к трансресвератролу антитела и их применение